In September of 2022, AlgometRx was awarded two Phase 1 SBIR awards from the National Cancer Institute (NCI) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The NCI award will be used to advance our investigation of Pediatric Vincristine Induced Peripheral Neuropathy (VIPN). The award from NIAMS will further our investigation into the assessment of disease activity in patients with Lupus.
top of page
Search
Recent Posts
See AllWe’re thrilled to share that AlgometRx has been featured in Nature Outlook: Pain! The article, "How a ‘pain-o-meter’ could improve...
AlgometRx was selected as a winner of the Washington Business Journal and DC Inno Fire Awards of 2021. Click here to view the article to...
bottom of page
Comentarios